BioRestorative Therapies (BRTX) AI Stock Analysis

• Market Cap: $13.36M
• Dividend Yield: N/A
• Average Volume (3M): 38.88K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: 175.03%
• EPS Growth: 55.34%
• Country: US
• Employees: 11
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -1.20
• Shares Outstanding: 7,504,780
• 10 Day Avg. Volume: 26,358
• 30 Day Avg. Volume: 38,875
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.06
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -2.21
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $8.00
• Price Target Upside: 354.55% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

BioRestorative Therapies faces significant financial challenges with ongoing net losses and negative cash flow, affecting its stock performance. However, recent improvements in financial metrics, substantial revenue growth, and promising clinical developments provide some optimism. Technical indicators suggest a neutral market position. Although valuation remains a concern due to the lack of profitability, the company's strategic focus on clinical trials and research offers potential for future growth.

Positive Factors

Efficacy Data

Positive signals are observed in the ongoing P2 study of BRTX-100, particularly as all four patients reached the response threshold in the interim data.

Market Position

BRTX-100 is the first cell therapy cleared for cervical spinal pain, potentially making this opportunity larger than lumbar spinal pain.

Regulatory Support

The ongoing Phase 2 trial in chronic lumbar disc disease (CLDD) recently received Fast Track designation from FDA.

Negative Factors

Trial Limitations

It is blinded, so definitive conclusions cannot be drawn.

BioRestorative Therapies Business Overview & Revenue Model

Company Description

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.

How the Company Makes Money

BioRestorative Therapies generates revenue through the development and commercialization of its proprietary cell and tissue-based therapeutic products. The company aims to earn revenue by advancing its clinical programs through various stages of regulatory approval, ultimately leading to product commercialization and sales. Key revenue streams include potential licensing agreements, strategic partnerships, and collaborations with pharmaceutical companies interested in its therapies. Additionally, BRTX may secure funding from grants and research subsidies as it progresses its clinical trials and expands its research initiatives. However, being a biotechnology company in the developmental stage, BioRestorative Therapies may also rely on equity financing and other forms of investment to support its operations until its therapies are fully developed and marketed.

BioRestorative Therapies Financial Statement Overview

Summary

BioRestorative Therapies is in a challenging financial position with consistent net losses and negative cash flows, despite some revenue growth. While the balance sheet shows reduced leverage and improved equity, the company's ability to generate cash and achieve profitability remains a significant concern. Continued focus on cost management and operational efficiency will be crucial for financial stability.

Income Statement

BioRestorative Therapies shows a significant increase in revenue year-over-year, but it remains small in absolute terms. Despite this, the company struggles with negative profitability metrics, including persistent net losses and negative EBIT and EBITDA margins, indicating ongoing operational challenges and high costs relative to revenue.

Balance Sheet

The company has improved its equity position with positive stockholders' equity, and it has no current total debt, reducing financial risk. However, the frequent large net losses impact the overall asset quality, and the equity ratio has been declining, signaling a need for better asset management.

Cash Flow

Operating cash flow has been consistently negative, reflecting ongoing cash outflows from operations. While free cash flow has seen slight improvement, it remains negative, indicating cash burn. The reliance on financing activities to support cash needs is evident, which may not be sustainable long-term without improved operational cash generation.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
401.00K	145.80K	119.80K	46.00K	77.00K
	Gross Profit
372.93K	145.80K	-160.87K	-159.21K	77.00K
	EBIT
-11.56M	-15.22M	-18.97M	-26.31M	-2.75M
	EBITDA
-11.56M	-15.06M	-18.85M	-26.22M	-9.48M
	Net Income Common Stockholders
-8.98M	-10.42M	-18.02M	-29.94M	-12.25M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
10.73M	11.07M	14.75M	21.03M	3.06M
	Total Assets
12.28M	12.61M	16.43M	22.45M	4.35M
	Total Debt
0.00	162.32K	301.64K	670.70K	4.79M
	Net Debt
-547.89K	-722.06K	-1.37M	-20.36M	1.73M
	Total Liabilities
3.75M	2.61M	602.62K	856.50K	5.68M
	Stockholders Equity
8.53M	10.00M	15.83M	21.60M	-1.33M
Cash Flow		Free Cash Flow
-8.23M	-6.60M	-6.31M	-3.36M	-1.96M
	Operating Cash Flow
-8.23M	-6.43M	-5.87M	-3.33M	-1.96M
	Investing Cash Flow
514.53K	3.25M	-13.48M	-30.66K	0.00
	Financing Cash Flow
7.38M	2.35M	0.00	21.32M	5.03M

BioRestorative Therapies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.76
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRTX, the sentiment is Positive. The current price of 1.76 is above the 20-day moving average (MA) of 1.75, above the 50-day MA of 1.72, and above the 200-day MA of 1.70, indicating a bullish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 51.00 is Neutral, neither overbought nor oversold. The STOCH value of 52.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BRTX.

BioRestorative Therapies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.28B	3.75	-42.72%	2.86%	17.70%	2.03%
BRTX	48 Neutral	$13.36M	―	-96.89%	―	175.03%	55.34%
PHIO	42 Neutral	$9.17M	―	-114.83%	―	―	81.71%
IMNN	41 Neutral	$12.28M	―	-211.21%	―	―	24.16%
MEIP	41 Neutral	$13.59M	―	-93.69%	―	-100.00%	-292.59%
COCP	40 Underperform	$15.36M	―	-97.50%	―	―	9.46%
INAB	34 Underperform	$13.73M	―	-154.44%	―	―	38.53%

BioRestorative Therapies Corporate Events

BioRestorative Clarifies Recent Press Release Details

BioRestorative Therapies has released a statement clarifying that the information in their recent press release is being furnished and not filed, and will not be incorporated into any registration statement unless specifically identified. The company emphasizes that this does not constitute a determination or admission that the information is material or complete, nor should it be considered by investors for making investment decisions.

BioRestorative Therapies Issues Regulation FD Disclosure

The news release does not contain specific information about BioRestorative Therapies’ industry, primary products or services, or market focus. The release appears to reference a Current Report on Form 8-K without providing substantial details about the company’s operations or implications for stakeholders.